The FDA has approved the orphan drug fedratinib (Inrebic) capsules, made by Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation, to treat adult patients with certain types of myelofibrosis, according to a press release from the agency.
AUGUST 20, 2019